Ambit Biosciences Corp. (NASDAQ: AMBI) has announced that it is entering into a merger with Daiichi Sankyo. All outstanding shares of Ambit will be acquired by Daiichi Sankyo for $15 each which will total approximately $315 million. While this is a huge premium, 24/7 Wall St. wants to see if this is actually a high enough price for Ambit’s shareholders to want to go along with the deal without a fight.
In addition to the acquisition of all the common stock, each stockholder of Ambit will receive one Contingent Value Right (CVR), which will entitle the holder to receive an additional cash payment of up to $4.50 for each share if certain commercialization milestones are reached. The whole transaction is valued at up to $410 million on a fully diluted basis.
Recently the stock has traded at $15.20, which is up 85% from the previous close of $8.20 on Friday. The stock had been rising at a slower rate prior to Monday, up from its low of $4.80 in July.
Ambit’s shares had fallen since nearly a year ago, until it reached its low in July, and have since made a strong recovery.
The primary reason for the acquisition was for Ambit’s experimental drug quizartinib, which treats myeloid leukemia in adults. This type of acute adult leukemia is the most common and reportedly makes up 36% of all new cases in 2014.
When asked about the acquisition, Daiichi Sankyo President and Chief Executive Officer Joji Nakayama said: “The acquisition of Ambit Biosciences further builds our presence in oncology to ensure we are delivering on our goal of providing world class, innovative pharmaceuticals in core areas of unmet medical need.”
The company has a consensus price target of $14.00 and a 52-week trading range of $4.80 to $21.44. It has a market cap of $273 million. Deals with CVRs often trade at a slight premium to a purchase price, and that CVR might not be of value for quite some time — if ever.
ALSO READ: 3 Likely Biotech Buyout Candidates
Want to Retire Early? Start Here (Sponsor)
Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Have questions about retirement or personal finance? Email us at [email protected]!
By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.
By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
